Could pharmacogenetic data explain part of the interindividual sensitivity to methadone-induced respiratory depression?

Critical Care

Volumn 11, Issue 1, 2007, Pages

  Crettol, Séverine ^a   Monnat, Martine ^b   Eap, Chin B ^a  

^a Hopital de Cery   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; METHADONE; MU OPIATE RECEPTOR; NARCOTIC AGENT;

CHEMICALLY INDUCED DISORDER; GENETIC POLYMORPHISM; GENETICS; HUMAN; METABOLISM; NOTE; RESPIRATORY FAILURE; RISK FACTOR;

CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; METHADONE; NARCOTICS; POLYMORPHISM, GENETIC; RECEPTORS, OPIOID, MU; RESPIRATORY INSUFFICIENCY; RISK FACTORS;

EID: 34248209578     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc5699     Document Type: Note

References (13)

1. Megarbane B, Decleves X, Bloch V, Bardin C, Chast F, Baud F. Case report: quantification of methadone-induced respiratory depression using toxicokinetic/toxicodynamic relationships. Crit Care 2007, 11:R5. 10.1186/cc5150, 17224045.
2. Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: Implications for the treatment of opioid dependence. Clin Pharmacokinet 2002, 41:1153-1193. 10.2165/00003088-200241140-00003, 12405865.
3. Crettol S, Déglon JJ, Besson J, Croquette-Krokkar M, Gothuey I, Hämmig R, Monnat M, Hüttemann H, Baumann P, Eap CB. Methadone enantiomer plasma levels, CYP2B6, CYP2C19 and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther 2005, 78:593-604. 10.1016/j.clpt.2005.08.011, 16338275.
4. Crettol S, Déglon JJ, Besson J, Croquette-Krokkar M, Hämmig R, Gothuey I, Monnat M, Eap CB. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther 2006, 80:668-681. 10.1016/j.clpt.2006.09.012, 17178267.
5. Begré S, von Bardeleben U, Ladewig D, Jaquet-Rochat S, Cosendai-Savary L, Powell Golay K, Kosel M, Baumann P, Eap CB. Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers. J Clin Psychopharmacol 2002, 22:211-215. 10.1097/00004714-200204000-00017, 11910269.
6. Eap CB, Bertschy G, Powell K, Baumann P. Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone. J Clin Psychopharmacol 1997, 17:113-117. 10.1097/00004714-199704000-00010, 10950475.
7. Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004, 75:13-33. 10.1016/j.clpt.2003.09.012, 14749689.
8. Schinkel AH, Wagenaar E, Mol CA, van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996, 97:2517-2524. 507337, 8647944.
9. Eap CB, Cuendet C, Baumann P. Binding of d-methadone, l-methadone, and dl-methadone, and to proteins in plasma of healthy volunteers: role of the variants of alpha1-acid glycoprotein. Clin Pharmacol Ther 1990, 47:338-346.
10. Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L, Gong J, Schluger J, Strong JA, Leal SM, et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters b-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci USA 1998, 95:9608-9613. 21386, 9689128, 10.1073/pnas.95.16.9608.
11. Lötsch J, Skarke C, Wieting J, Oertel BG, Schmidt H, Brockmöller J, Geisslinger G. Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action. Clin Pharmacol Ther 2006, 79:72-89. 10.1016/j.clpt.2005.09.010, 16413243.
12. Oertel BG, Schmidt R, Schneider A, Geisslinger G, Lötsch J. The mu-opioid receptor gene polymorphism 118A>G depletes alfentanil-induced analgesia and protects against respiratory depression in homozygous carriers. Pharmacogenet Genomics 2006, 16:625-636.
13. Klepstad P, Rakvag TT, Kaasa S, Holthe M, Dale O, Borchgrevink PC, Baar C, Vikan T, Krokan HE, Skorpen F. The 118A>G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand 2004, 48:1232-1239. 10.1111/j.1399-6576.2004.00517.x, 15504181.